Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
188.51
272.8
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Zhangzhou Pientzehuang Pharmaceutical Co Ltd stock under the Base Case scenario is 162.22 CNY. Compared to the current market price of 236 CNY, Zhangzhou Pientzehuang Pharmaceutical Co Ltd is Overvalued by 31%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for Zhangzhou Pientzehuang Pharmaceutical Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. is a beacon of traditional Chinese medicine, rooted in a legacy that dates back over four decades. Specializing in the production of proprietary herbal medicines, particularly its flagship product, Pientzehuang, the company expertly marries ancient healing practices with modern pharmaceutical standards. The company's commitment to quality and innovation is evident in its meticulous sourcing of raw materials and rigorous R&D efforts, positioning it as a leader in the herbal medicine sector. Zhangzhou's extensive distribution network spans both domestic and international markets, enhancing its brand recognition and further entrenching its product...
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. is a beacon of traditional Chinese medicine, rooted in a legacy that dates back over four decades. Specializing in the production of proprietary herbal medicines, particularly its flagship product, Pientzehuang, the company expertly marries ancient healing practices with modern pharmaceutical standards. The company's commitment to quality and innovation is evident in its meticulous sourcing of raw materials and rigorous R&D efforts, positioning it as a leader in the herbal medicine sector. Zhangzhou's extensive distribution network spans both domestic and international markets, enhancing its brand recognition and further entrenching its products in the hearts and homes of patients seeking natural remedies.
As the global demand for alternative healthcare solutions continues to rise, Zhangzhou Pientzehuang stands at the forefront of this burgeoning market. The company's unwavering focus on expanding its product line and leveraging e-commerce platforms provides lucrative opportunities for growth. Additionally, its strategic partnerships with healthcare institutions and researchers underscore its credibility and commitment to advancing healthcare. For investors, Zhangzhou Pientzehuang represents not merely an investment in a company, but a stake in the revival and global acceptance of traditional Chinese medicine, a field that resonates with the increasing emphasis on holistic health and wellness. With a robust business model and a future poised for expansion, the company stands as an attractive candidate for those looking to invest in the convergence of tradition and modern healthcare innovation.
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. is well-known for its traditional Chinese medicine products and has several core business segments. Here are the main segments:
-
Traditional Chinese Medicine (TCM) Products: Pientzehuang is primarily recognized for its flagship product, Pientzehuang, a TCM formulation that is used for various health conditions. The company focuses on research and development of TCM, emphasizing both production and the use of herbal medicines.
-
Pharmaceuticals: In addition to TCM, the company also develops and markets Western pharmaceuticals, which could include over-the-counter medications and prescription drugs.
-
Healthcare Products: Pientzehuang may offer a range of healthcare products, including dietary supplements and functional foods, targeting consumers interested in health and wellness.
-
Research and Development: A significant part of the company’s strategy involves innovation through R&D to enhance traditional medicine formulations and develop new products, ensuring efficacy and safety.
-
International Business Development: Beyond its domestic market, Zhangzhou Pientzehuang has been working on international expansion, exporting its products to various countries and aiming to tap into overseas markets.
-
Online Sales and E-commerce: Increasingly, the company is leveraging e-commerce platforms to reach customers directly, which is vital in China's rapidly evolving retail landscape.
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. focuses on integrating traditional practices with modern research methodologies, aiming at both niche markets and broader consumer health trends.
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. has several unique competitive advantages that distinguish it from its rivals in the pharmaceutical industry:
-
Specialized Product Focus: Pientzehuang is known for its specialized products, particularly in traditional Chinese medicine (TCM). The company's flagship product, Pientzehuang, is recognized for its effective treatment of various conditions and has established a strong brand reputation.
-
Cultural Heritage and Trust: The company's deep roots in traditional Chinese medicine provide it a unique positioning in the market. Many consumers in China and beyond have a growing trust in TCM, and Pientzehuang benefits from this cultural affinity.
-
Research and Development: Pientzehuang invests significantly in research and development to modernize and enhance its traditional products. This commitment not only ensures product efficacy but also aids regulatory compliance and potential international market entry.
-
Strong Distribution Network: The company has developed an extensive distribution network across China, allowing for effective penetration into various markets and easier access for consumers to its products.
-
Regulatory Expertise: Navigating the complex landscape of pharmaceutical regulations can be a challenge. Pientzehuang’s expertise in regulatory affairs, particularly in the TCM sector, gives it an edge over competitors who may lack this specialized knowledge.
-
Brand recognition and loyalty: With decades of market presence, Pientzehuang has built a strong brand identity and consumer loyalty, which can be a significant barrier for new entrants or smaller rivals.
-
Innovative International Expansion Strategies: The company has been proactive in exploring international markets, leveraging its traditional product strengths while also adapting to local preferences and regulatory frameworks.
-
Quality Control and Standards: Pientzehuang emphasizes high standards in manufacturing and quality control, aligning with both domestic and international standards, which enhances consumer confidence and sets it apart from competitors.
-
Strategic Partnerships: Collaborations with research institutions and healthcare providers enhance its innovation capabilities and market reach, helping it stay ahead in the competitive landscape.
These competitive advantages help Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. navigate the complexities of the pharmaceutical market while effectively catering to the growing demand for traditional and modern medicine solutions.
Zhangzhou Pientzehuang Pharmaceutical Co. Ltd., like many companies in the pharmaceutical industry, faces a variety of risks and challenges that could impact its operations and growth in the near future. Here are some key risks and challenges:
-
Regulatory Risks: The pharmaceutical sector is heavily regulated. Changes in regulations, approval processes, or compliance requirements could pose significant challenges. Delays in getting approvals for new drugs or treatments can impact profitability and market position.
-
Market Competition: The pharmaceutical industry is highly competitive, with numerous players vying for market share. Increased competition, particularly from generics or biosimilars, could pressure pricing and market share.
-
Intellectual Property Risks: Protecting intellectual property (IP) is crucial for pharmaceutical companies. Patent expirations can lead to the introduction of generic versions of drugs, which can significantly reduce revenues.
-
Supply Chain Disruptions: Global supply chains can be vulnerable to disruptions from geopolitical tensions, natural disasters, or pandemics. Such disruptions could impact the availability of raw materials or essential components for manufacturing.
-
R&D Challenges: Pharmaceutical companies rely on successful research and development (R&D) for innovation. High costs, long timelines, and the risk of clinical trial failures pose significant challenges in bringing new products to market.
-
Economic Factors: Economic conditions, such as inflation or recession, can affect healthcare spending and insurance coverage, which in turn could impact sales.
-
Public Perception and Trust: Health crises can significantly influence public perception. Issues related to drug safety, pricing, or ethical practices can undermine consumer trust and affect demand.
-
International Expansion Risks: If Zhangzhou Pientzehuang seeks to expand its presence internationally, it could face various challenges including cultural differences, varying regulatory environments, and local competition.
-
Technological Advancements: The pace of technological advancement in pharmaceuticals, such as personalized medicine or digital health technologies, means the company must adapt quickly or risk obsolescence.
-
Environmental and Social Governance (ESG) Factors: Increasing focus on ESG issues can present challenges. Companies may face pressure to operate sustainably, and failure to meet these expectations can lead to reputational damage or regulatory unsustainability.
To navigate these challenges, the company may need to adopt strategic planning, invest in R&D, and maintain a robust risk management framework.
Revenue & Expenses Breakdown
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Balance Sheet Decomposition
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Current Assets | 15.1B |
Cash & Short-Term Investments | 9.1B |
Receivables | 1.1B |
Other Current Assets | 4.9B |
Non-Current Assets | 1.9B |
Long-Term Investments | 571.9m |
PP&E | 854.4m |
Intangibles | 279.1m |
Other Non-Current Assets | 215.7m |
Current Liabilities | 2.5B |
Accounts Payable | 470.9m |
Accrued Liabilities | 620.1m |
Short-Term Debt | 1.1B |
Other Current Liabilities | 327.4m |
Non-Current Liabilities | 850.4m |
Long-Term Debt | 158.1m |
Other Non-Current Liabilities | 692.3m |
Earnings Waterfall
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Revenue
|
10.7B
CNY
|
Cost of Revenue
|
-5.9B
CNY
|
Gross Profit
|
4.8B
CNY
|
Operating Expenses
|
-1.3B
CNY
|
Operating Income
|
3.4B
CNY
|
Other Expenses
|
-463.5m
CNY
|
Net Income
|
3B
CNY
|
Free Cash Flow Analysis
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
CNY | |
Free Cash Flow | CNY |
Profitability Score
Profitability Due Diligence
Zhangzhou Pientzehuang Pharmaceutical Co Ltd's profitability score is 74/100. The higher the profitability score, the more profitable the company is.
Score
Zhangzhou Pientzehuang Pharmaceutical Co Ltd's profitability score is 74/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Zhangzhou Pientzehuang Pharmaceutical Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Zhangzhou Pientzehuang Pharmaceutical Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for Zhangzhou Pientzehuang Pharmaceutical Co Ltd is 280.87 CNY with a low forecast of 176.75 CNY and a high forecast of 375.9 CNY.
Dividends
Current shareholder yield for Zhangzhou Pientzehuang Pharmaceutical Co Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. engages in the manufacture and sale of Chinese medicines. The company is headquartered in Zhangzhou, Fujian and currently employs 2,591 full-time employees. The company went IPO on 2003-06-16. The firm is also engaged in the production and sales of cosmetics and daily chemical products and the circulation of medicine. The firm's core products are PianZi Huang series products, including PianZi Huang, PianZi Huang capsule, compound PianZi Huang buccal tablets, compound PianZi Huang ointment, compound PianZi Huang hemorrhoids ointment and others, covering many fields such as liver disease medication, cold medication, dermatology medication. The firm's products are sold to domestic and overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one Zhangzhou Pientzehuang Pharmaceutical Co Ltd stock under the Base Case scenario is 162.22 CNY.
Compared to the current market price of 236 CNY, Zhangzhou Pientzehuang Pharmaceutical Co Ltd is Overvalued by 31%.